OMERACT endorsement of patient-reported outcome instruments in antineutrophil cytoplasmic antibody–associated vasculitis

OMERACT endorsement of patient-reported outcome instruments in antineutrophil cytoplasmic antibody–associated vasculitis

<strong>Objective.</strong> The antineutrophil cytoplasmic antibody–associated vasculitides (AAV) are multiorgan diseases. Patients with AAV report impairment in their health-related quality of life (HRQOL) and have different priorities regarding disease assessment compared with physicia...

Full description

Bibliographic Details
Main Authors:	Robson, J, Tomasson, G, Milman, N, Ashdown, S, Boonen, A, Casey, G, Cronholm, P, Cuthbertson, D, Dawson, J, Direskeneli, H, Easley, E, Kermani, T, Farrar, J, Gebhart, D, Lanier, G, Luqmani, R, Mahr, A, McAlear, C, Peck, J, Shea, B, Shea, J, Sreih, A, Tugwell, P, Merkel, P
Format:	Journal article
Language:	English
Published:	Journal of Rheumatology 2017

Similar Items

Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure
by: Robson, J, et al.
Published: (2018)

Scale Structure and Measurement Properties of a Disease Specific Patient-Reported Outcome for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
by: Robson, J, et al.
Published: (2016)

A disease-specific patient-reported outcome for anti-neutrophil cytoplasmic antibody–associated vasculitis: scale structure and measurement properties of the anti-neutrophil cytoplasmic antibody-associated vasculitis patient-reported outcome measure
by: Robson, J, et al.
Published: (2017)

A disease-specific patient-reported outcome for ANCA associated vasculitis: scale structure and measurement properties of the AAV- PRO
by: Robson, J, et al.
Published: (2017)

Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis
by: Robson, J, et al.
Published: (2017)

Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire
by: Robson, J, et al.
Published: (2018)

Feasibility and construct validation of the patient reported outcomes measurement information system in systemic vasculitis
by: Tomasson, G, et al.
Published: (2019)

The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.
by: Merkel, P, et al.
Published: (2011)

Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7.
by: Merkel, P, et al.
Published: (2005)

PsAID12 provisionally endorsed at OMERACT 2018 as core outcome measure to assess psoriatic arthritis-specific health-related quality of life in clinical trials
by: Orbai, A, et al.
Published: (2018)

The OMERACT core domain set for clinical trials of shoulder disorders
by: Ramiro, S, et al.
Published: (2019)

Glucocorticoid Treatment and Damage In The Antineutrophil- Cytoplasm Antibody Associated Vasculitides
by: Robson, J, et al.
Published: (2013)

Endorsement of the 66/68 joint count for the measurement of musculoskeletal disease activity: OMERACT 2018 psoriatic arthritis workshop report
by: Duarte-García, A, et al.
Published: (2019)

The Omeract-Oarsi core set of outcome domains to measure in clinical trials for people with hip and/or knee osteoarthritis
by: Smith, T, et al.
Published: (2018)

Current status of outcome measure development in vasculitis.
by: Merkel, P, et al.
Published: (2014)

Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9.
by: Merkel, P, et al.
Published: (2009)

ANTINEUTROPHIL ANTIBODY AND PRIMARY SCLEROSING CHOLANGITIS
by: Lo, S, et al.
Published: (1991)

Uptake of the OMERACT-OARSI hip and knee osteoarthritis core outcome set: review of randomised controlled trials from 1997 to 2017
by: Smith, T, et al.
Published: (2019)

Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis.
by: Walsh, M, et al.
Published: (2011)

Antineutrophil antibody: a test for autoimmune primary sclerosing cholangitis in childhood?
by: Lo, S, et al.
Published: (1993)

OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF
by: Leung, Y-Y, et al.
Published: (2021)

Goodpasture's syndrome with antineutrophil cytoplasmic antibodies
by: Losada, E, et al.
Published: (1993)

Antineutrophil cytoplasmic antibodies in autoimmune hepatitis.
by: Bansi, D, et al.
Published: (1995)

Early outcomes in children with antineutrophil cytoplasmic antibody-associated vasculitis
by: Morishita, K, et al.
Published: (2017)

Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.
by: Direskeneli, H, et al.
Published: (2011)

The OMERACT-OARSI core domain set for measurement in clinical trials of hip and/or knee osteoarthritis
by: Smith, T, et al.
Published: (2019)

Caveolin-1 single nucleotide polymorphism in antineutrophil cytoplasmic antibody associated vasculitis
by: Chand, S, et al.
Published: (2013)

Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease.
by: Harper, L, et al.
Published: (2004)

ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES AFTER LIVER-TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS
by: Bansi, D, et al.
Published: (1995)

A severe, antineutrophil cytoplasmic antibody associated, anterior segment vasculitis.
by: Talks, S, et al.
Published: (1994)

Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.
by: Mukhtyar, C, et al.
Published: (2006)

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.
by: Mukhtyar, C, et al.
Published: (2008)

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies
by: Tillett, W, et al.
Published: (2017)

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
by: De Groot, K, et al.
Published: (2005)

Antigen specificity of antineutrophil antibodies in ulcerative colitis, primary sclerosing and autoimmune hepatitis.
by: Bansi, D, et al.
Published: (1996)

Cardiovascular outcomes in antineutrophil cytoplasm antibody associated vasculitis (AAV)
by: Mukhtyar, C, et al.
Published: (2008)

Content and face validity and feasibility of 5 candidate instruments for psoriatic arthritis randomized controlled trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting
by: Holland, R, et al.
Published: (2018)

Antigen specificity of antineutrophil antibodies in ulcerative colitis, primary sclerosing cholangitis and autoimmune hepatitis
by: Bansi, D, et al.
Published: (1996)

Characterisation of the antigen for the antineutrophil cytoplasmic antibody specific for primary sclerosing cholangitis
by: Cameron, B, et al.
Published: (1998)

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
by: Flossmann, O, et al.
Published: (2006)